Evidence map›Paper›PMID 25424576›Full record

ArticleImmunologic research2014

Olfactory impairment in patients with the fibromyalgia syndrome and systemic sclerosis.

Howard Amital, Nancy Agmon-Levin, Netta Shoenfeld, Yoav Arnson, Daniela Amital, Pnina Langevitz, Alexandra Balbir Gurman, Yehuda Shoenfeld

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04178616 (Assessment of the Prevalence of Olfactory Disorders in Systemic Scleroderma), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04178616 naterminatednot on this mapstarted 2019, after this paper: background citation

Assessment of the Prevalence of Olfactory Disorders in Systemic Scleroderma

TypeinterventionalSponsorUniversity Hospital, LilleRan2019 to 2020Enrolled59ConditionsOlfactory Disorders, SclerodermaArmsolfactory testing with specific odorants (localisation and identification)
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. International consensus statement on allergy and rhinology: Olfaction.International forum of allergy & rhinology · 2022
    Review
  6. Article
  7. Review
  8. SARS-CoV-2, the autoimmune virus.Autoimmunity reviews · 2020
    Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Howard AmitalSackler Faculty of Medicine, Tel-Aviv University, 52621, Tel Aviv, Israel, hamital@netvision.net.il.
Nancy Agmon-Levin
Netta Shoenfeld
Yoav Arnson
Daniela Amital
Pnina Langevitz
Alexandra Balbir Gurman
Yehuda Shoenfeld
Sheba Medical Center · ILTel Aviv University · ILMeir Medical Center · ILTechnion – Israel Institute of Technology · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with autoimmune diseases often present with olfactory impairment. The aim of the study was to assess the olfactory functions of female patients with fibromyalgia (FM) compared with patients with systemic sclerosis (SSc) and with healthy female controls. Olfactory functions were assessed in 24 patients with FM, 20 patients with SSc and 21 age-matched healthy controls. The sense of smell was evaluated using the Sniffin' Sticks test including the three stages of smell: threshold, discrimination, and identification (TDI) of the different odors. The severity of fibromyalgia was assessed using the fibromyalgia impact questionnaire (FIQ). The short form 36 (SF-36) questionnaire was also completed in order to seek a relationship between the patients perception of quality of life and the different aspects of the smell sense. Depression was evaluated in both FM and SSc patients utilizing the Beck depression inventory-II (BDI-II) questionnaire. Patients with FM had significantly lower TDI smell scores compared with both SSc patients and healthy controls (p < 0.005, One-Way ANOVA). Hyposmia (defined as TDI scores below 30) were observed in 14 of 24 (42 %) patients with FM compared to 3 of 20 (15 %) patients with SSc and 1 of the healthy controls (4.3 %) (p < 0.02). FM patients had significantly lower thresholds of smell compared to both healthy controls and patients with SSc (p < 0.001), whereas for patients with SSc only the ability to discriminate between odors was impaired (p < 0.006). We could not detect any statistical correlation between smell abilities and clinical manifestation of SSc or the FIQ and SF-36 scores among FM patients. However the correlation between depression, defined by the BDI-II score, and the sense of smell differed between patients with FM and patients with SSc. As only among SSc patients a lower sense of smell correlated with a higher BDI-II score (p = 0.02). Our findings suggest that there is a decrease in the sense of smell both in FM and SSc patients compared with healthy controls. However these impairments differ between patients group and might represent different mechanisms that affect the sense of smell.

Indexed as

AdultAgedDepressionFemaleFibromyalgiaHumansMiddle AgedOlfaction DisordersQuality of LifeScleroderma, SystemicSeverity of Illness IndexYoung Adult

Identifiers

PMID25424576
OpenAlexW2041553003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.